Key clinical point: An antithrombotic regimen consisting of apixaban and a P2Y12 inhibitor without aspirin provides superior safety and similar efficacy in patients with AFib and ACS.
Major finding: Apixaban compared with a vitamin K antagonist reduced bleeding among patients with ACS treated medically (HR, 0.44) or with PCI (HR, 0.68), and in those undergoing elective PCI (HR, 0.82) (P for interaction = .052).
Study details: A prespecified analysis of 4,614 patients in the AUGUSTUS trial.
Disclosures: AUGUSTUS was funded by Bristol-Myers Squibb and Pfizer Inc. Dr. Windecker reported having received institutional research and educational grants to Bern University Hospital from Abbott, Amgen, Bayer, BMS, CSL Behring, Boston Scientific, Biotronik, Edwards Lifesciences, Medtronic, Polares, and Sinomed. His coauthors reported having numerous financial ties to the pharmaceutical and device industries.
Windecker S et al. TCT 2019, Late-Breaking Trials 1 session.